Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M, Crump M, Vredenburgh JJ, Petros WP, Hussein A, Rubin P, Ross M, Gilbert C, Modlin C, Meisenberg B, Coniglio D, Rabinowitz J, Laughlin M, Kurtzberg J, Peters WP. Elkordy M, et al. Among authors: vredenburgh jj. Bone Marrow Transplant. 1997 Feb;19(4):315-22. doi: 10.1038/sj.bmt.1700633. Bone Marrow Transplant. 1997. PMID: 9051240 Clinical Trial.
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
Stuart MJ, Peters WP, Broadwater G, Hussein A, Ross M, Marks LB, Folz RJ, Long GD, Rizzieri D, Chao NJ, Vredenburgh JJ. Stuart MJ, et al. Among authors: vredenburgh jj. Biol Blood Marrow Transplant. 2002;8(12):666-73. doi: 10.1053/bbmt.2002.v8.abbmt080666. Biol Blood Marrow Transplant. 2002. PMID: 12523579 Clinical Trial.
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.
Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, Hussein A, Rizzieri D, Marks LB, Gilbert C, Affronti ML, Moore S, McDonald C, Petros WP, Peters WP. Vredenburgh JJ, et al. Biol Blood Marrow Transplant. 2006 Feb;12(2):195-203. doi: 10.1016/j.bbmt.2005.10.009. Biol Blood Marrow Transplant. 2006. PMID: 16443517 Free article. Clinical Trial.
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affrontil ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Person D, Berry DA, Peters WP. Hussein AM, et al. Among authors: vredenburgh jj. Cancer Chemother Pharmacol. 1996;37(6):561-8. doi: 10.1007/s002800050429. Cancer Chemother Pharmacol. 1996. PMID: 8612310 Clinical Trial.
168 results